Sana Biotechnology (NASDAQ:SANA) Trading Down 6.4% – Time to Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA) was down 6.4% during trading on Monday . The stock traded as low as $3.96 and last traded at $3.96. Approximately 422,683 shares traded hands during trading, a decline of 81% from the average daily volume of 2,202,793 shares. The stock had previously closed at $4.23.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SANA shares. Citigroup boosted their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 target price on the stock. Finally, HC Wainwright decreased their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Sana Biotechnology Trading Down 2.8 %

The firm has a market cap of $839.50 million, a price-to-earnings ratio of -2.52 and a beta of 1.42. The firm has a 50 day moving average price of $4.70 and a 200-day moving average price of $6.22.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, equities analysts expect that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current fiscal year.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently bought and sold shares of SANA. Vanguard Group Inc. raised its holdings in Sana Biotechnology by 24.1% in the first quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock valued at $121,552,000 after acquiring an additional 2,358,089 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Sana Biotechnology by 2.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock worth $36,956,000 after acquiring an additional 101,434 shares during the period. Capital World Investors increased its holdings in shares of Sana Biotechnology by 255.8% in the 1st quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock worth $54,490,000 after acquiring an additional 3,917,728 shares during the period. Integral Health Asset Management LLC grew its position in Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after buying an additional 220,000 shares in the last quarter. Finally, Baillie Gifford & Co. grew its position in Sana Biotechnology by 5.0% in the 1st quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock valued at $106,563,000 after buying an additional 506,262 shares in the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.